AKT1 and urinary bladder carcinoma: Thymoquinone's attenuation of the PI3K/Akt signalling pathway to inhibit cell growth, proliferation, and angiogenesis is observed in HTB-9 bladder cancer; MDA-MB-468 and T47D breast cancer and; TFK-1 and HuCCT1 cholangio-carcinoma [118,120,122].